Enovis Regeneration offers evidence-based, non-invasive bone growth stimulation solutions designed to support fracture healing and spinal fusion outcomes while helping payers address avoidable costs, high-cost complications, and care variability.
Our portfolio includes technologies for fresh fractures, nonunion fractures, and spinal fusion patients, providing treatment options that support value-based care initiatives and more efficient musculoskeletal care pathways.
Improved healing outcomes across fracture and spinal fusion populations
Reduced reliance on high-cost surgical interventions
Lower inpatient utilization and episode complexity
Support for opioid reduction initiatives
Protocol-driven management of high-risk patient populations
Scalable, non-invasive treatment pathways across the continuum of care
The Cost of Delayed Healing
Failure to heal following a fracture or spinal fusion can result in significant downstream costs, including hospitalizations, revision procedures, prolonged rehabilitation, opioid utilization, and extended episodes of care. Published literature demonstrates that nonunion and pseudarthrosis are associated with substantially higher healthcare utilization and cost burden compared to successful healing.
By supporting the body's natural healing process, bone growth stimulation may help reduce progression to these costly events while improving recovery trajectories for appropriate patients.
Supporting Better Outcomes Across the Care Continuum
For payers, improved healing can translate into fewer complications, fewer escalations to surgery, reduced readmissions, and lower overall episode costs.
- Accelerated healing for indicated fresh fractures
- High healing rates in nonunion fracture populations
- Reduced time to spinal fusion
- Increased fusion success rates compared with non-stimulation controls
- Improved patient recovery and reduced complication risk
Enovis technologies are supported by clinical evidence demonstrating meaningful improvements in fracture healing and spinal fusion outcomes. Published studies have reported:
Managing Financial Risk Before It Escalates
Early intervention with non-invasive bone growth stimulation offers an opportunity to proactively manage risk before patients progress into higher-cost treatment pathways. Published analyses have demonstrated reductions in surgical utilization, inpatient admissions, inpatient costs, and overall healthcare expenditures among bone stimulation users compared with control groups.
Nonunion fractures and failed spinal fusions represent some of the most expensive complications in musculoskeletal care. These events frequently drive:
- Additional surgeries
- Repeat procedures
- Hospital admissions
- Extended rehabilitation
- Long-term disability and productivity loss
Addressing Clinical and Behavioral Health Challenges
For health plans focused on whole-person care, improving healing outcomes may contribute to lower pharmacy costs, reduced risk of opioid dependence, and improved member satisfaction.
Pain remains a major driver of healthcare utilization following fractures and spinal fusion procedures. Published literature suggests that successful healing is associated with:
- Lower pain levels
- Reduced opioid utilization
- Shorter opioid treatment duration
- Improved quality of life measures
- Better functional recovery
A Targeted Approach to Improving Outcomes
Bone growth stimulation may provide an opportunity to focus resources on higher-risk populations where complications and avoidable costs are most likely to occur. This targeted approach supports utilization management strategies while helping optimize patient outcomes.
Certain populations are known to experience increased risk of nonunion and fusion failure, including patients with:
- Diabetes
- Obesity
- Smoking history
- Osteoporosis
- Revision surgery history
- Multi-level procedures
- Advanced age and other comorbidities
Enovis Regeneration Solutions
Manafuse™
Low Intensity Pulsed Ultrasound (LIPUS) technology indicated for established nonunions and certain fresh fractures. Manafuse features a convenient 20-minute daily wear time and supports early intervention across the fracture care pathway.
Potential Value Drivers
- Accelerated healing of indicated fresh fractures
- Support for early fracture intervention
- Reduced risk of progression to high-cost nonunion
- Simple patient compliance through low daily wear time
OL1000™
Combined Magnetic Field (CMF) technology indicated for established fracture nonunions secondary to trauma. Designed for difficult-to-heal fractures, OL1000 offers a non-invasive alternative to surgery for appropriate patients.
Potential Value Drivers
- High reported healing rates in nonunion populations
- Reduced dependency on invasive procedures
- Lower complication and infection exposure
- Improved episode predictability and cost
Spinalogic®
CMF technology indicated as an adjunct treatment to primary lumbar spinal fusion surgery for one or two levels. Spinalogic supports successful fusion and may help reduce the utilization and costs associated with pseudarthrosis and revision surgery.
Potential Value Drivers
- Improved fusion success rates
- Faster time to fusion
- Reduced reoperation risk
- Opportunity to focus treatment on high-risk patient populations